Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient
Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Bone Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352187224000032 |
| _version_ | 1797247817424568320 |
|---|---|
| author | Bhanvi Ramchandani Faryal Sardar Mirza |
| author_facet | Bhanvi Ramchandani Faryal Sardar Mirza |
| author_sort | Bhanvi Ramchandani |
| collection | DOAJ |
| description | Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe osteoporosis and primary biliary cholangitis (PBC). Using half dose RSB (approximately 3 mg/kg RSB), she demonstrated significant improvement in lumbar spine BMD, paralleling the results of phase III trials. This case highlights the effectiveness of RSB in a patient with concomitant PBC, in addition to its effectiveness at half the recommended dose in an underweight patient. |
| first_indexed | 2024-03-08T13:19:52Z |
| format | Article |
| id | doaj.art-96e82a61061a41108915e8f129f41fe8 |
| institution | Directory Open Access Journal |
| issn | 2352-1872 |
| language | English |
| last_indexed | 2024-04-24T20:04:43Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Bone Reports |
| spelling | doaj.art-96e82a61061a41108915e8f129f41fe82024-03-24T06:59:11ZengElsevierBone Reports2352-18722024-03-0120101736Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patientBhanvi Ramchandani0Faryal Sardar Mirza1University of Connecticut Primary Care Internal Medicine Residency Program, 263 Farmington Avenue, Farmington, CT 06030, USAUConn Health, Division of Endocrinology and Metabolism, 263 Farmington Avenue, Farmington, CT 06030, USA; Corresponding author.Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe osteoporosis and primary biliary cholangitis (PBC). Using half dose RSB (approximately 3 mg/kg RSB), she demonstrated significant improvement in lumbar spine BMD, paralleling the results of phase III trials. This case highlights the effectiveness of RSB in a patient with concomitant PBC, in addition to its effectiveness at half the recommended dose in an underweight patient.http://www.sciencedirect.com/science/article/pii/S2352187224000032Post-menopausal osteoporosisRomosozumabPrimary biliary cholangitisFracturesMonoclonal antibodies |
| spellingShingle | Bhanvi Ramchandani Faryal Sardar Mirza Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient Bone Reports Post-menopausal osteoporosis Romosozumab Primary biliary cholangitis Fractures Monoclonal antibodies |
| title | Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient |
| title_full | Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient |
| title_fullStr | Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient |
| title_full_unstemmed | Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient |
| title_short | Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient |
| title_sort | effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient |
| topic | Post-menopausal osteoporosis Romosozumab Primary biliary cholangitis Fractures Monoclonal antibodies |
| url | http://www.sciencedirect.com/science/article/pii/S2352187224000032 |
| work_keys_str_mv | AT bhanviramchandani effectivenessofromosozumabinprimarybiliarycholangitisathalftherecommendeddoseinanunderweightpatient AT faryalsardarmirza effectivenessofromosozumabinprimarybiliarycholangitisathalftherecommendeddoseinanunderweightpatient |